Lesson plan
SRX251
SRX251, or SRX-251, also known as API-251, is a selective vasopressin V 1A receptor antagonist that is or was under development for the treatment of aggression. It was also being developed for the treatment of dysmenorrhea, but development for this indication was discontinued. The drug is taken by mouth. SRX251 reduces aggressive behavior in rodents. It is or was being developed by Azevan Pharmaceuticals. In 2007, it was in phase 1 clinical trials.
Article summary
SRX251, or SRX-251, also known as API-251, is a selective vasopressin V 1A receptor antagonist that is or was under development for the treatment of aggression. It was also being developed for the treatment of dysmenorrhea, but development for this indication was discontinued. The drug is taken by mouth. SRX251 reduces aggressive behavior in rodents. It is or was being developed by Azevan Pharmaceuticals. In 2007, it was in phase 1 clinical trials.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.